The endothelial lipase protein is promising urinary biomarker for diagnosis of gastric cancer

Diagnostic Pathology

Fan Li³  Ying Xu⁴  Qing Yang³  Ai Cui³  Juan Cui²  Jian Suo¹  Zhaohui Ni³  Guoqing Zhang⁵  Guoqing Wang³  Xueyan Dong³ 

[1] The First Hospital of Jilin University Norman Bethune Medical College, Changchun, Jilin, 130021, China;Computational Systems Biology Laboratory, Department of Biochemistry and Molecular Biology, and Institute of Bioinformatics, University of Georgia, Athens, GA, 30602-7229, USA;Department of Pathogeny Biology, Norman Bethune Medical College of Jilin University, 126 Xinmin street, Changchun, Jilin, 130021, China;College of Computer Science and Technology, Jilin University, Changchun, Jilin, 130012, China;Cancer Hospital Affiliated with Xinjiang Medical University, Urumqi, Xinjiang, 830000, China

关键词: Diagnosis;    Gastric cancer;    Biomarker;    Endothelial lipase;   

Others  :  807361
DOI  :  10.1186/1746-1596-8-45

 received in 2012-12-20, accepted in 2013-03-10,  发布年份 2013

【 摘 要 】

Background

Gastric cancer is one of the most common malignant tumors in the world. Finding effective diagnostic biomarkers in urine or serum would represent the most ideal solution to detecting gastric cancer during annual physical examination. This study was to evaluate the potential of endothelial lipase (EL) as a urinary biomarker for diagnosis of gastric cancer.

Methods

The expression levels of EL was measured using Western blotting and immunohistochemical staining experiments on (tissue, serum, and urine) samples of gastric cancer patients versus healthy people. We also checked the EL levels in the urine samples of other cancer types (lung, colon and rectum cancers) and benign lesions (gastritis and gastric leiomyoma) to check if EL was specific to gastric cancer.

Result

We observed a clear separation between the EL expression levels in the urine samples of 90 gastric cancer patients and of 57 healthy volunteers. It was approximately 9.9 fold average decrease of the EL expression levels in the urine samples of gastric cancer compared to the healthy controls (P <0.0001), achieving a 0.967 AUC value for the ROC (receiver operating characteristic) curve, demonstrating it’s highly accurate as a diagnostic marker for gastric cancer. Interestingly, the expression levels of EL in tissue and serum samples were not nearly as discriminative as in urine samples (P = 0.90 and P = 0.79). In immunohistochemical experiments, positive expression of the EL protein was found in 67% (8/12) of gastric adjacent noncancerous and in 58% (7/12) of gastric cancer samples. There was no significant statistical in the expression levels of this protein between the gastric cancer and the matching noncancerous tissues (P =0.67).

Conclusions

The urinary EL as a highly accurate gastric cancer biomarker that is potentially applicable to the general screening with high sensitivity and specificity.

Virtual Slides

The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/4527331618757552 webcite

【 授权许可】

   
2013 Dong et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
• [2]Bertuccio P, Chatenoud L, Levi F, Praud D, Ferlay J, Negri E, Malvezzi M, La Vecchia C: Recent patterns in gastric cancer: a global overview. Int J Cancer 2009, 125:666-673.
• [3]Wu K, Nie Y, Guo C, Chen Y, Ding J, Fan D: Molecular basis of therapeutic approaches to gastric cancer. J Gastroenterol Hepatol 2009, 24:37-41.
• [4]Jin J, Jin T, Quan M, Piao Y, Lin Z: Ezrin overexpression predicts the poor prognosis of gastric adenocarcinoma. Diagn Pathol 2012, 7:135. BioMed Central Full Text
• [5]Ren J, Chen Z, Juan SJ, Yong XY, Pan BR, Fan DM: Detection of circulating gastric carcinoma-associated antigen MG7-Ag in human sera using an established single determinant immuno-polymerase chain reaction technique. Cancer 2000, 88:280-285.
• [6]Xu Y, Zhang L, Hu G: Potential application of alternatively glycosylated serum MUC1 and MUC5AC in gastric cancer diagnosis. Biologicals 2009, 37:18-25.
• [7]Kon OL, Yip TT, Ho MF, Chan WH, Wong WK, Tan SY, Ng WH, Kam SY, Eng A, Ho P: The distinctive gastric fluid proteome in gastric cancer reveals a multi-biomarker diagnostic profile. BMC Med Genomics 2008, 1:54. BioMed Central Full Text
• [8]Adachi J, Kumar C, Zhang Y, Olsen JV, Mann M: The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins. Genome Biol 2006, 7:R80. BioMed Central Full Text
• [9]Feldman AS, Banyard J, Wu CL, McDougal WS, Zetter BR: Cystatin B as a tissue and urinary biomarker of bladder cancer recurrence and disease progression. Clin Cancer Res 2009, 15:1024-1031.
• [10]Hazzaa SM, Elashry OM, Afifi IK: Clusterin as a diagnostic and prognostic marker for transitional cell carcinoma of the bladder. Pathol Oncol Res 2009, 16:101-109.
• [11]Zavada J, Zavadova Z, Zat’ovicova M, Hyrsl L, Kawaciuk I: Soluble form of carbonic anhydrase IX (CA IX) in the serum and urine of renal carcinoma patients. Br J Cancer 2003, 89:1067-1071.
• [12]Vasudev NS, Sim S, Cairns DA, Ferguson RE, Craven RA, Stanley A, Cartledge J, Thompson D, Selby PJ, Banks RE: Pre-operative urinary cathepsin D is associated with survival in patients with renal cell carcinoma. Br J Cancer 2009, 101:1175-1182.
• [13]Pories SE, Zurakowski D, Roy R, Lamb CC, Raza S, Exarhopoulos A, Scheib RG, Schumer S, Lenahan C, Borges V: Urinary metalloproteinases: noninvasive biomarkers for breast cancer risk assessment. Cancer Epidemiol Biomarkers Prev 2008, 17:1034-1042.
• [14]Yamaguchi T, Takahashi T, Yokota T, Kitamura K, Noguchi A, Kamiguchi M, Doi M, Ahn T, Sawai K, Yamane T: Urinary pepsinogen I as a tumor marker of stomach cancer after total gastrectomy. Cancer 1991, 68:906-909.
• [15]Dong LM, Shu XO, Gao YT, Milne G, Ji BT, Yang G, Li HL, Rothman N, Zheng W, Chow WH, Abnet CC: Urinary prostaglandin E2 metabolite and gastric cancer risk in the Shanghai women’s health study. Cancer Epidemiol Biomarkers Prev 2009, 18:3075-3078.
• [16]Tsigris C, Karayiannakis AJ, Syrigos KN, Zbar A, Diamantis T, Kalahanis N, Alexiou D: Clinical significance of soluble c-erbB-2 levels in the serum and urine of patients with gastric cancer. Anticancer Res 2002, 22:3061-3065.
• [17]Cui J, Chen Y, Chou WC, Sun L, Chen L, Suo J, Ni Z, Zhang M, Kong X, Hoffman LL: An integrated transcriptomic and computational analysis for biomarker identification in gastric cancer. Nucleic Acids Res 2010, 39:1197-1207.
• [18]Hong CS, Cui J, Ni Z, Su Y, Puett D, Li F, Xu Y: A computational method for prediction of excretory proteins and application to identification of gastric cancer markers in urine. PLoS One 2011, 6:e16875.
• [19]Hirata K, Dichek HL, Cioffi JA, Choi SY, Leeper NJ, Quintana L, Kronmal GS, Cooper AD, Quertermous T: Cloning of a unique lipase from endothelial cells extends the lipase gene family. J Biol Chem 1999, 274:14170-14175.
• [20]Jaye M, Lynch KJ, Krawiec J, Marchadier D, Maugeais C, Doan K, South V, Amin D, Perrone M, Rader DJ: A novel endothelial-derived lipase that modulates HDL metabolism. Nat Genet 1999, 21:424-428.
• [21]Rader DJ, Jaye M: Endothelial lipase: a new member of the triglyceride lipase gene family. Curr Opin Lipidol 2000, 11:141-147.
• [22]Annema W, Tietge UJ: Role of hepatic lipase and endothelial lipase in high-density lipoprotein-mediated reverse cholesterol transport. Curr Atheroscler Rep 2011, 13:257-265.
• [23]Yasuda T, Ishida T, Rader DJ: Update on the role of endothelial lipase in high-density lipoprotein metabolism, reverse cholesterol transport, and atherosclerosis. Circ J 2010, 74:2263-2270.
• [24]Huang J, Qian HY, Li ZZ, Zhang JM, Wang S, Tao Y, Gao YL, Yin CQ, Que B, Sun T: Role of endothelial lipase in atherosclerosis. Transl Res 2010, 156:1-6.
• [25]Wu X, Huang H, Tang F, Le K, Xu S, Liu P: Regulated expression of endothelial lipase in atherosclerosis. Mol Cell Endocrinol 2010, 315:233-238.
• [26]Takasu S, Mutoh M, Takahashi M, Nakagama H: Lipoprotein lipase as a candidate target for cancer prevention/therapy. Biochem Res Int 2012, 2012:398697.
• [27]Lu J, Li J, Ji C, Yu W, Xu Z, Huang S: Expression of lipoprotein lipase associated with lung adenocarcinoma tissues. Mol Biol Rep 2008, 35:59-63.
• [28]Nielsen JE, Lindegaard ML, Friis-Hansen L, Almstrup K, Leffers H, Nielsen LB, Rajpert-De Meyts E: Lipoprotein lipase and endothelial lipase in human testis and in germ cell neoplasms. Int J Androl 2004, 33:e207-e215.
• [29]Haraldsson B, Sorensson J: Why do we not all have proteinuria? An update of our current understanding of the glomerular barrier. News Physiol Sci 2004, 19:7-10.
• [30]Griffon N, Jin W, Petty TJ, Millar J, Badellino KO, Saven JG, Marchadier DH, Kempner ES, Billheimer J, Glick JM, Rader DJ: Identification of the active form of endothelial lipase, a homodimer in a head-to-tail conformation. J Biol Chem 2009, 284:23322-23330.
• [31]Parks SK, Chiche J, Pouyssegur J: pH control mechanisms of tumor survival and growth. J Cell Physiol 2011, 226:299-308.
• [32]Demirag GG, Sullu Y, Gurgenyatagi D, Okumus NO, Yucel I: Expression of plakophilins (PKP1, PKP2, and PKP3) in gastric cancers. Diagn Pathol 2011, 6:1. BioMed Central Full Text
• [33]Lee J, Seo JW, Jun HJ, Ki CS, Park SH, Park YS, Lim HY, Choi MG, Bae JM, Sohn TS: Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target. Oncol Rep 2011, 25:1517-1524.
• [34]Zhao J, Zhang X, Xin Y: Up-regulated expression of Ezrin and c-Met proteins are related to the metastasis and prognosis of gastric carcinomas. Histol Histopathol 2011, 26:1111-1120.